SureNano Science Ltd (SURE) AI Stock Analysis

• Market Cap: C$10.17M
• Dividend Yield: N/A
• Average Volume (3M): 666.00
• Price to Earnings (P/E): ―
• Beta (1Y): -2.81
• Revenue Growth: N/A
• EPS Growth: 91.27%
• Country: CA
• Employees: N/A
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals - Specialty
• EPS (TTM): -0.01
• Shares Outstanding: 33,907,800
• 10 Day Avg. Volume: 950
• 30 Day Avg. Volume: 666
• PEG Ratio: 0.37
• Price to Book (P/B): -21.52
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -10.64
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: C$0.28 ▼(-5.33% Downside)
• Action: Upgraded Date: 12/30/25
• Date: Action: Upgraded 12/30/25

The score is primarily held down by very weak financial performance (zero recent revenue, ongoing losses and cash burn, and negative equity). Technicals provide partial support due to a strong uptrend, but overbought signals raise near-term risk. Recent financing improves liquidity somewhat, while valuation remains unattractive due to continued losses and no dividend.

Positive Factors

Low Leverage / No Reported Debt

Absence of reported debt reduces interest and near-term refinancing burdens, giving management time to execute a turnaround or operational reset. This structural advantage lowers immediate solvency pressure and preserves cash flow flexibility while revenue and margins are rebuilt.

Recent Financing Improves Liquidity

Securing a $1.25M private placement provides incremental runway and signals investor willingness to fund operations. Structurally, fresh capital reduces immediate default risk, funds near-term operational needs, and creates the optionality to pursue product development or commercialization steps.

Executive Incentive Alignment

Granting options creates longer-term alignment between management and shareholders, aiding retention and focus on value-creating milestones. In a turnaround context, equity-linked incentives help prioritize execution of strategic initiatives and can improve consistency of management decisions.

Negative Factors

Zero Recent Revenue

A sustained absence of revenue removes the business's underwriting for fixed costs and growth investments. Without a recurring sales base, the company must rely on external funding to operate, leaving long-term viability dependent on reestablishing product-market traction.

Persistent Operating Losses

Chronic negative operating results erode capital and limit reinvestment capacity. Ongoing losses increase dependence on dilutive financing, constrain strategic flexibility, and make achieving sustainable margins harder without a meaningful recovery in revenue.

Negative Shareholders' Equity

Negative equity reflects accumulated losses and weakened capitalization, reducing borrowing capacity and increasing perceived insolvency risk. This structural balance-sheet weakness raises the likelihood of further dilution or restructuring to restore financial resilience.

SureNano Science Ltd Business Overview & Revenue Model

Company Description

SureNano Science Ltd. operates as a nanotechnology supply company in Canada and Colorado, the United States. The company distributes SureNano surfactant, a ready-to-mix food-grade compound that provides the base for high performance hemp and cannabis nano-emulsions. Its SureNano surfactant has applications in products, such as CBD, hemp-infused sprays, beverages, food items, and tropical products. The company was incorporated in 2021 and is headquartered in Vancouver, Canada.

How the Company Makes Money

SureNano Science Ltd generates revenue through the commercialization of its proprietary nanotechnology solutions. Key revenue streams include the sale of nanomaterials and related products to industrial clients, licensing agreements for its patented technologies, and collaborative partnerships with other companies for joint development projects. The company may also receive funding from grants or research partnerships aimed at advancing nanotechnology applications. Significant partnerships with industry leaders or research institutions can enhance its market reach and contribute to its earnings.

SureNano Science Ltd Financial Statement Overview

Summary

Financials are highly stressed: persistent losses with negative EBIT/EBITDA, operating and free cash flow negative in every year shown, and revenue effectively at zero in 2023–2025. No reported debt helps near-term solvency risk, but equity turned negative in 2024 and worsened in 2025, indicating weakened capitalization and reliance on external funding.

Income Statement

Operating performance remains weak: the company has reported losses in every year shown, with negative EBIT/EBITDA throughout. Revenue has effectively disappeared in the last three annual periods (2023–2025 revenue at 0), limiting visibility on the path to profitability. A positive from earlier years is that gross profit was strong when revenue existed (2021–2022), but the current run-rate shows no meaningful top-line to absorb fixed costs, keeping earnings deeply negative.

Balance Sheet

Leverage appears low on the surface with no reported debt across periods, which reduces near-term financial risk from interest and refinancing. However, the balance sheet has deteriorated sharply: shareholders’ equity turned negative in 2024 and fell further in 2025, signaling accumulated losses and a weakened capital base. Total assets have also contracted materially versus 2021–2023 levels, reducing financial flexibility and increasing reliance on future financing to sustain operations.

Cash Flow

Cash generation is consistently negative: operating cash flow and free cash flow are below zero in every year shown, indicating ongoing cash burn. While cash burn improved from 2023 to 2024 and remains better than the 2022 peak outflow, 2025 still shows substantial negative operating and free cash flow, suggesting the business is not self-funding. The company’s cash flow profile implies continued dependence on external capital unless operations materially improve.

Breakdown	TTM	Mar 2024	Jun 2023	Jun 2022	Mar 2022	Mar 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	18.00K	36.00K
Gross Profit	-1.88K	-2.50K	-2.50K	-3.75K	16.51K	34.66K
EBITDA	-407.27K	-57.09K	-277.39K	-380.27K	-1.12M	-81.59K
Net Income	-226.77K	-59.59K	-279.89K	-384.02K	-1.12M	-82.51K
Balance Sheet
Total Assets	1.20M	54.27K	153.11K	317.61K	686.44K	966.81K
Cash, Cash Equivalents and Short-Term Investments	1.17M	23.49K	134.80K	276.99K	667.09K	929.01K
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	34.16K	134.04K	173.29K	57.90K	36.49K	17.32K
Stockholders Equity	1.17M	-79.77K	-20.18K	259.71K	649.95K	949.49K
Cash Flow
Free Cash Flow	-208.53K	-161.31K	-142.19K	-403.63K	-669.76K	-102.99K
Operating Cash Flow	-208.53K	-161.31K	-142.19K	-383.63K	-669.76K	-102.99K
Investing Cash Flow	0.00	0.00	0.00	-6.47K	0.00	0.00
Financing Cash Flow	1.39M	50.00K	0.00	0.00	407.85K	1.03M

SureNano Science Ltd Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.30
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:SURE, the sentiment is Neutral. The current price of 0.3 is below the 20-day moving average (MA) of 0.30, below the 50-day MA of 0.31, and above the 200-day MA of 0.17, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 48.24 is Neutral, neither overbought nor oversold. The STOCH value of 49.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:SURE.

SureNano Science Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VNP	76 Outperform	C$2.75B	39.06	26.65%	―	30.36%	181.15%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
NEO	50 Neutral	C$1.15B	-126.59	-1.61%	2.55%	8.04%	-195.66%
GMG	50 Neutral	C$260.27M	-27.25	-92.59%	―	6.29%	-3.71%
SURE	46 Neutral	C$10.17M	-27.27	―	―	―	91.27%
CNO	42 Neutral	C$14.60M	-4.74	-61.05%	―	-15.84%	-375.96%
NANO	42 Neutral	C$106.41M	-7.07	-64.59%	―	―	56.03%

SureNano Science Ltd Corporate Events

SureNano Buys GlucaPharm to Drive Next-Generation GLP-1 Drug Push

SureNano Science Ltd. has completed the acquisition of GlucaPharm Inc., gaining control of GEP44, a patented, second-generation GLP peptide that has shown significant weight-loss and blood-glucose benefits in preclinical studies with fewer gastrointestinal side effects than first-generation drugs such as Ozempic and Mounjaro. The all-share deal, which includes locked-up stock and warrants, accelerates SureNano’s shift into a near-term pharmaceutical value creator and is supported by the appointment of veteran drug developer Dr. Nihar R. Pandey as director and chief scientific officer.

GlucaPharm’s program targets the rapidly expanding GLP market with a differentiated asset that may be deliverable via non-injectable routes such as oral, sublingual or nasal formulations, a feature management believes could broaden patient adoption and deepen market penetration. The company is working with an Australian contract research organization to advance an IND-enabling FDA study and a Phase I trial in Australia, with key regulatory and early clinical milestones expected over the next six to nine months, positioning SureNano to compete in one of the decade’s most lucrative pharmaceutical segments.

The most recent analyst rating on (TSE:SURE) stock is a Hold with a C$0.30 price target. To see the full list of analyst forecasts on SureNano Science Ltd stock, see the TSE:SURE Stock Forecast page.

SureNano Science Ltd. Grants 1.5 Million Stock Options to Key Personnel

SureNano Science Ltd. has announced the granting of 1,500,000 stock options to its directors, officers, and consultants. These options, which vest immediately, are exercisable at CAD $0.18 per share over five years, representing 4.4% of the company’s outstanding common shares. This move is likely aimed at incentivizing key personnel and aligning their interests with the company’s growth objectives.

SureNano Science Ltd. Completes $1.25 Million Private Placement

SureNano Science Ltd. has successfully closed a $1,250,000 private placement, issuing 10,000,000 units at $0.125 per unit. Each unit includes a common share and a warrant, with warrants allowing purchase of additional shares at $0.35 within 24 months. The funds raised will support operating expenses, market expansion for the SureNano™ surfactant, and potential business combinations or acquisitions, enhancing the company’s operational capabilities and market positioning.